Replay available

Galderma Group Ag (GDERF) Q3 2025 Earnings Call

Galderma Group Ag (OTC: GDERF) Q3 2025 earnings conference call, held 2025-10-23. Replay captured from the company's public earnings webcast.

Thu, October 23, 2025 at 3:30 PMendedReplay
Galderma Group Ag (GDERF) Q3 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Dr. Flemming Ornskov

Chief Executive Officer

Thomas Dietrich

Chief Financial Officer

Unknown Morgan Stanley Analyst

Analyst, Morgan Stanley

Harry Sefton

Analyst, UBS

Shyam Kotadia

Analyst, Goldman Sachs

Benjamin Jackson

Analyst, Jefferies

Yihang Li

Analyst, Barclays

Victor Floch

Analyst, BNP Paribas Exane

Richard Vosser

Analyst, J.P. Morgan

Natalia Webster

Analyst, RBC

Replay transcript excerpt

Welcome to Goderma's 2025 third quarter trading update call. As customary, the press release was published at 7 a.m. Central European Standard Time today and can be viewed on our corporate website at any time. Today's presentation slides, as well as a recording of the webcast, will be made available on our website after the call. Please be advised that today's presentation contains forward-looking statements, which should be treated with the appropriate level of caution as advised on the slide. Let me now introduce today's trading updates webcast. Dr. Flemming Ornskov, CEO of GoDerma, will provide performance highlights for the third quarter. Thomas Dietrich, CFO, will then present the trading update and the financial outlook for the full financial year. Both Flemming and Thomas will be available to answer questions from financial analysts before Flemming provides his final remarks to close the webcast. With this, I would like to invite Flemming to start the GoDerma's highlights for the third quarter of 2025. Flemming, over to you. Thank you, Emil. Good morning, good afternoon, and welcome to Gelderma's third quarter 2025 trading update webcast. In a year of opportunities, we delivered record net sales for the first nine months, along with strong commercial and innovation momentum across our portfolio. For the first nine months, Gelderma delivered 3.7 billion US dollars in net sales. These results are ahead of expectation, driven by focused execution of both the existing portfolio and new innovation. Growth was driven primarily by volume, complemented by favorable mix. For the period, net sales growth was up 15% year on year at constant currency. Growth for the third quarter was up 21% year on year at constant currency. This represents an acceleration across all geog...

More from Galderma Group Ag